Hints and tips:
Related Special Reports
...So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years....
...fibrosis treatment....
...Strand Therapeutics, a developer of mRNA therapeutics for cancer immunotherapy, and Arcturus Therapeutics, which is using mNRA to combat cystic fibrosis, are also potential targets, the people said....
...Vertex, a maker of a treatment for cystic fibrosis, and Seattle Genetics, which won earlier-than-expected approval for its new breast cancer drug, have outperformed....
...Sandoz admitted rigging the prices of drugs including benazepril HCTZ, which is used to treat hypertension, skin treatments such as clobetasol, and a drug used to treat cystic fibrosis sufferers who have...
...For example, English patients with cystic fibrosis have been waiting for years for a deal between Nice and Vertex, a biotech company with a life-changing treatment with a US list price of $272,000 (it is...
...But Vertex Pharmaceuticals, which develops medicines for cystic fibrosis, defied the general gloom....
...Vertex Pharmaceuticals’ shares spiked nearly 25 per cent in after-hours trading on Tuesday, following positive data from studies of several three-drug combinations used to treat cystic fibrosis....
...If those trials are successful, Crispr, Editas and a third company, Intellia Therapeutics, say they plan to study the technique in humans with a range of diseases including cancer, cystic fibrosis, haemophilia...
...fibrosis....
...About 75,000 people worldwide have cystic fibrosis, an inherited disease caused by defects in a gene that controls water and salt levels in cells....
...And Jeffrey Leiden, chief executive of Vertex, a large biotech group focused on cystic fibrosis, linked the Allergan case to the wider debate over pricing....
...fibrosis — although it refrained from offering genetic health reports....
...Both the US, the acknowledged global leader, and China are pursuing personalised treatments for diseases such as cancer, cystic fibrosis or Alzheimer’s....
...Watching on as a guest of the US president was a cystic fibrosis patient called Bill Elder....
...Roughly 70,000 people suffer from the disease worldwide, including 30,000 in the US, according to the Cystic Fibrosis Foundation....
...Vertex, another up-and-coming pharma group, recently launched Kalydeco, a cystic fibrosis pill that costs $300,000 a year....
...Some 75,000 people in those regions suffer from cystic fibrosis, which congests the lungs and has no cure....
...Forecasts for Vertex’s much-anticipated cystic fibrosis treatment range between a low of $1.3bn and a high of $2.8bn in 2016, which could represent three-quarters of the company’s overall sales....
...Vertex Pharmaceuticals’ shares soared on Tuesday after the biotechnology company said results from a late-stage trial of its cystic fibrosis treatment met its primary goals....
...Shares in Vertex Pharmaceuticals fell 9 per cent to $67.12 on concerns about the company’s experimental drug to treat cystic fibrosis, VX809....
...Take, for example, a cystic-fibrosis drug, called Kalydeco, made by Vertex Pharmaceuticals, which costs $300,000 a year....
...Aptalis, which focuses on treatments for cystic fibrosis and gastrointestinal disorders in North America and Europe, had filed papers last month to pursue an initial public offering....
...Last month Forest bought Aptalis, a specialist in treatments for cystic fibrosis and gastrointestinal disorders, for $2.9bn from private equity group TPG....
...IMS highlights the broader use of innovative medicines ahead including oral rheumatoid arthritis drugs, cystic fibrosis treatments, and medicines for melanoma and prostate cancer....
International Edition